Publicly-traded company PTC Therapeutics Inc. (NASDAQ:PTCT) had a closing price of $40.91 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $50.63, this means that the stock is underpriced by 19.2%. In the past 52 weeks the company’s stock price has moved within the range of $27.53 to $48.81.
This particular stock’s 5-day moving average is 40.55, its 20-day moving average is 37.46 and its 100-day moving average is 41.72. PTC Therapeutics Inc. (PTCT) currently has 61.60M shares outstanding, which means that its market capitalization is $2.52B.
The Details: PTC Therapeutics Inc. (PTCT) Financial Health
There are a number of indicators we can consider when wondering about a potential stock’s financial health. Looking at a company’s profit margin, for example, tells us how much of its sales revenue it keeps in earnings – and it is calculated by taking net income and dividing it by net sales. PTCT currently has a profit margin of -74.90%.
Checking out a company’s operating margin is also useful, as it tells us how much profit is retained after considering operating costs and depreciation. PTC Therapeutics Inc. (PTCT) has an operating margin of -71.90%.
Return on Assets is a number, expressed as a percentage that tells us how well a publicly-traded company is using its current assets to generate revenue. The higher the percentage, the better a company is using its assets to turn a profit. At the moment, PTC Therapeutics Inc. Return on Assets is -16.70%.
What Does Wall Street Say about Company?
When choosing stocks, many investors search for what Wall Street professionals think about the company first – like what the average rating is. At the moment, the average analyst rating for PTCT is Overweight. Out of 10 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 3 rated it hold, and 6 rated it a Buy.
Understanding Profitability at PTC Therapeutics Inc. (PTCT)
Taking a look at a public company’s Earnings per Share (EPS) is a good way of evaluating its profitability. In the most recent financial results released by PTC Therapeutics Inc., for the quarter ending on 12/2019, the company posted EPS of -0.20. The average estimate of Wall Street analysts had projected 0.10.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.37, compared to -0.96 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 7 analysts is 95.33M – compared to 86.34M posted in the year-ago period.